Morphea associated with the use of adalimumab: a case report and review of the literature
Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ramírez, Julio [verfasserIn] Hernández, M. Victoria [verfasserIn] Galve, Javier [verfasserIn] Cañete, Juan D. [verfasserIn] Sanmartí, Raimon [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2011 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Modern rheumatology - Oxford : Oxford University Press, 2000, 22(2011), 4 vom: 18. Nov., Seite 602-604 |
|---|---|
| Übergeordnetes Werk: |
volume:22 ; year:2011 ; number:4 ; day:18 ; month:11 ; pages:602-604 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10165-011-0550-4 |
|---|
| Katalog-ID: |
SPR009026061 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR009026061 | ||
| 003 | DE-627 | ||
| 005 | 20230519115606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10165-011-0550-4 |2 doi | |
| 035 | |a (DE-627)SPR009026061 | ||
| 035 | |a (SPR)s10165-011-0550-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.83 |2 bkl | ||
| 100 | 1 | |a Ramírez, Julio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Morphea associated with the use of adalimumab: a case report and review of the literature |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment. | ||
| 650 | 4 | |a Ankylosing spondylitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antirheumatic agents |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug toxicity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Localized scleroderma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tumor necrosis factor-alpha |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hernández, M. Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Galve, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Cañete, Juan D. |e verfasserin |4 aut | |
| 700 | 1 | |a Sanmartí, Raimon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Modern rheumatology |d Oxford : Oxford University Press, 2000 |g 22(2011), 4 vom: 18. Nov., Seite 602-604 |w (DE-627)320627497 |w (DE-600)2023498-3 |x 1439-7609 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2011 |g number:4 |g day:18 |g month:11 |g pages:602-604 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10165-011-0550-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4328 | ||
| 912 | |a GBV_ILN_4333 | ||
| 936 | b | k | |a 44.83 |q ASE |
| 951 | |a AR | ||
| 952 | |d 22 |j 2011 |e 4 |b 18 |c 11 |h 602-604 | ||
| author_variant |
j r jr m v h mv mvh j g jg j d c jd jdc r s rs |
|---|---|
| matchkey_str |
article:14397609:2011----::opeascaewttesoaaiuaaaeeotnr |
| hierarchy_sort_str |
2011 |
| bklnumber |
44.83 |
| publishDate |
2011 |
| allfields |
10.1007/s10165-011-0550-4 doi (DE-627)SPR009026061 (SPR)s10165-011-0550-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Ramírez, Julio verfasserin aut Morphea associated with the use of adalimumab: a case report and review of the literature 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment. Ankylosing spondylitis (dpeaa)DE-He213 Antirheumatic agents (dpeaa)DE-He213 Drug toxicity (dpeaa)DE-He213 Localized scleroderma (dpeaa)DE-He213 Tumor necrosis factor-alpha (dpeaa)DE-He213 Hernández, M. Victoria verfasserin aut Galve, Javier verfasserin aut Cañete, Juan D. verfasserin aut Sanmartí, Raimon verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 22(2011), 4 vom: 18. Nov., Seite 602-604 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:22 year:2011 number:4 day:18 month:11 pages:602-604 https://dx.doi.org/10.1007/s10165-011-0550-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 22 2011 4 18 11 602-604 |
| spelling |
10.1007/s10165-011-0550-4 doi (DE-627)SPR009026061 (SPR)s10165-011-0550-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Ramírez, Julio verfasserin aut Morphea associated with the use of adalimumab: a case report and review of the literature 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment. Ankylosing spondylitis (dpeaa)DE-He213 Antirheumatic agents (dpeaa)DE-He213 Drug toxicity (dpeaa)DE-He213 Localized scleroderma (dpeaa)DE-He213 Tumor necrosis factor-alpha (dpeaa)DE-He213 Hernández, M. Victoria verfasserin aut Galve, Javier verfasserin aut Cañete, Juan D. verfasserin aut Sanmartí, Raimon verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 22(2011), 4 vom: 18. Nov., Seite 602-604 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:22 year:2011 number:4 day:18 month:11 pages:602-604 https://dx.doi.org/10.1007/s10165-011-0550-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 22 2011 4 18 11 602-604 |
| allfields_unstemmed |
10.1007/s10165-011-0550-4 doi (DE-627)SPR009026061 (SPR)s10165-011-0550-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Ramírez, Julio verfasserin aut Morphea associated with the use of adalimumab: a case report and review of the literature 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment. Ankylosing spondylitis (dpeaa)DE-He213 Antirheumatic agents (dpeaa)DE-He213 Drug toxicity (dpeaa)DE-He213 Localized scleroderma (dpeaa)DE-He213 Tumor necrosis factor-alpha (dpeaa)DE-He213 Hernández, M. Victoria verfasserin aut Galve, Javier verfasserin aut Cañete, Juan D. verfasserin aut Sanmartí, Raimon verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 22(2011), 4 vom: 18. Nov., Seite 602-604 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:22 year:2011 number:4 day:18 month:11 pages:602-604 https://dx.doi.org/10.1007/s10165-011-0550-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 22 2011 4 18 11 602-604 |
| allfieldsGer |
10.1007/s10165-011-0550-4 doi (DE-627)SPR009026061 (SPR)s10165-011-0550-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Ramírez, Julio verfasserin aut Morphea associated with the use of adalimumab: a case report and review of the literature 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment. Ankylosing spondylitis (dpeaa)DE-He213 Antirheumatic agents (dpeaa)DE-He213 Drug toxicity (dpeaa)DE-He213 Localized scleroderma (dpeaa)DE-He213 Tumor necrosis factor-alpha (dpeaa)DE-He213 Hernández, M. Victoria verfasserin aut Galve, Javier verfasserin aut Cañete, Juan D. verfasserin aut Sanmartí, Raimon verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 22(2011), 4 vom: 18. Nov., Seite 602-604 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:22 year:2011 number:4 day:18 month:11 pages:602-604 https://dx.doi.org/10.1007/s10165-011-0550-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 22 2011 4 18 11 602-604 |
| allfieldsSound |
10.1007/s10165-011-0550-4 doi (DE-627)SPR009026061 (SPR)s10165-011-0550-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Ramírez, Julio verfasserin aut Morphea associated with the use of adalimumab: a case report and review of the literature 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment. Ankylosing spondylitis (dpeaa)DE-He213 Antirheumatic agents (dpeaa)DE-He213 Drug toxicity (dpeaa)DE-He213 Localized scleroderma (dpeaa)DE-He213 Tumor necrosis factor-alpha (dpeaa)DE-He213 Hernández, M. Victoria verfasserin aut Galve, Javier verfasserin aut Cañete, Juan D. verfasserin aut Sanmartí, Raimon verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 22(2011), 4 vom: 18. Nov., Seite 602-604 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:22 year:2011 number:4 day:18 month:11 pages:602-604 https://dx.doi.org/10.1007/s10165-011-0550-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 22 2011 4 18 11 602-604 |
| language |
English |
| source |
Enthalten in Modern rheumatology 22(2011), 4 vom: 18. Nov., Seite 602-604 volume:22 year:2011 number:4 day:18 month:11 pages:602-604 |
| sourceStr |
Enthalten in Modern rheumatology 22(2011), 4 vom: 18. Nov., Seite 602-604 volume:22 year:2011 number:4 day:18 month:11 pages:602-604 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Ankylosing spondylitis Antirheumatic agents Drug toxicity Localized scleroderma Tumor necrosis factor-alpha |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Modern rheumatology |
| authorswithroles_txt_mv |
Ramírez, Julio @@aut@@ Hernández, M. Victoria @@aut@@ Galve, Javier @@aut@@ Cañete, Juan D. @@aut@@ Sanmartí, Raimon @@aut@@ |
| publishDateDaySort_date |
2011-11-18T00:00:00Z |
| hierarchy_top_id |
320627497 |
| dewey-sort |
3610 |
| id |
SPR009026061 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009026061</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519115606.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2011 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-011-0550-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009026061</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-011-0550-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ramírez, Julio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Morphea associated with the use of adalimumab: a case report and review of the literature</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ankylosing spondylitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antirheumatic agents</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug toxicity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Localized scleroderma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumor necrosis factor-alpha</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hernández, M. Victoria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galve, Javier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cañete, Juan D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sanmartí, Raimon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">22(2011), 4 vom: 18. Nov., Seite 602-604</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:4</subfield><subfield code="g">day:18</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:602-604</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-011-0550-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2011</subfield><subfield code="e">4</subfield><subfield code="b">18</subfield><subfield code="c">11</subfield><subfield code="h">602-604</subfield></datafield></record></collection>
|
| author |
Ramírez, Julio |
| spellingShingle |
Ramírez, Julio ddc 610 bkl 44.83 misc Ankylosing spondylitis misc Antirheumatic agents misc Drug toxicity misc Localized scleroderma misc Tumor necrosis factor-alpha Morphea associated with the use of adalimumab: a case report and review of the literature |
| authorStr |
Ramírez, Julio |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)320627497 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1439-7609 |
| topic_title |
610 ASE 44.83 bkl Morphea associated with the use of adalimumab: a case report and review of the literature Ankylosing spondylitis (dpeaa)DE-He213 Antirheumatic agents (dpeaa)DE-He213 Drug toxicity (dpeaa)DE-He213 Localized scleroderma (dpeaa)DE-He213 Tumor necrosis factor-alpha (dpeaa)DE-He213 |
| topic |
ddc 610 bkl 44.83 misc Ankylosing spondylitis misc Antirheumatic agents misc Drug toxicity misc Localized scleroderma misc Tumor necrosis factor-alpha |
| topic_unstemmed |
ddc 610 bkl 44.83 misc Ankylosing spondylitis misc Antirheumatic agents misc Drug toxicity misc Localized scleroderma misc Tumor necrosis factor-alpha |
| topic_browse |
ddc 610 bkl 44.83 misc Ankylosing spondylitis misc Antirheumatic agents misc Drug toxicity misc Localized scleroderma misc Tumor necrosis factor-alpha |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Modern rheumatology |
| hierarchy_parent_id |
320627497 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Modern rheumatology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)320627497 (DE-600)2023498-3 |
| title |
Morphea associated with the use of adalimumab: a case report and review of the literature |
| ctrlnum |
(DE-627)SPR009026061 (SPR)s10165-011-0550-4-e |
| title_full |
Morphea associated with the use of adalimumab: a case report and review of the literature |
| author_sort |
Ramírez, Julio |
| journal |
Modern rheumatology |
| journalStr |
Modern rheumatology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2011 |
| contenttype_str_mv |
txt |
| container_start_page |
602 |
| author_browse |
Ramírez, Julio Hernández, M. Victoria Galve, Javier Cañete, Juan D. Sanmartí, Raimon |
| container_volume |
22 |
| class |
610 ASE 44.83 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ramírez, Julio |
| doi_str_mv |
10.1007/s10165-011-0550-4 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
morphea associated with the use of adalimumab: a case report and review of the literature |
| title_auth |
Morphea associated with the use of adalimumab: a case report and review of the literature |
| abstract |
Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment. |
| abstractGer |
Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment. |
| abstract_unstemmed |
Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 |
| container_issue |
4 |
| title_short |
Morphea associated with the use of adalimumab: a case report and review of the literature |
| url |
https://dx.doi.org/10.1007/s10165-011-0550-4 |
| remote_bool |
true |
| author2 |
Hernández, M. Victoria Galve, Javier Cañete, Juan D. Sanmartí, Raimon |
| author2Str |
Hernández, M. Victoria Galve, Javier Cañete, Juan D. Sanmartí, Raimon |
| ppnlink |
320627497 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10165-011-0550-4 |
| up_date |
2024-07-04T00:22:17.947Z |
| _version_ |
1803605810030313472 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009026061</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519115606.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2011 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-011-0550-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009026061</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-011-0550-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ramírez, Julio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Morphea associated with the use of adalimumab: a case report and review of the literature</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ankylosing spondylitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antirheumatic agents</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug toxicity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Localized scleroderma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumor necrosis factor-alpha</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hernández, M. Victoria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galve, Javier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cañete, Juan D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sanmartí, Raimon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">22(2011), 4 vom: 18. Nov., Seite 602-604</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:4</subfield><subfield code="g">day:18</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:602-604</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-011-0550-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2011</subfield><subfield code="e">4</subfield><subfield code="b">18</subfield><subfield code="c">11</subfield><subfield code="h">602-604</subfield></datafield></record></collection>
|
| score |
7.4011784 |